Last night, Oncodesign announced the entry into clinical development of its second drug candidate, with the dosing of a first patient in a Phase 1 trial.

The study will focus on its RIPK2 inhibitor, ODS-101, a novel therapeutic agent for the treatment of chronic inflammatory bowel diseases (IBD), such as Crohn's disease.

The goal of the precision medicine biopharmaceutical company is to fund the development of this molecule from its Nanocyclix technology platform through to Phase 2a clinical proof-of-concept, scheduled for 2024.

Prior to this, Oncodesign intends to determine the most appropriate clinical indication for the continuation of this Phase I, before looking for a pharmaceutical partner.

Last September, Oncodesign had already announced the entry into clinical phase of its first drug candidate, a treatment for Parkinson's disease developed in partnership with the Servier laboratory.

Listed on the Paris Bourse, Oncodesign shares gained 3.9% on Friday in the wake of this announcement.

Copyright (c) 2023 CercleFinance.com. All rights reserved.